SCHEMBL2449732

SCHEMBL2449732

CCCCCc1ccccc1C(=O)SC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.49
CYSLTR2 Q9NS75 9/20 0.47
CYSLTR1 Q9Y271 9/20 0.47
BID P55957 3/20 0.45
MCL1 Q07820 3/20 0.45
BCL2L1 Q07817 2/20 0.45
BAK1 Q16611 2/20 0.45
KAT8 Q9H7Z6 2/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
EP300 Q09472 1/20 0.45
KAT2A Q92830 1/20 0.45
KAT2B Q92831 1/20 0.45
KAT5 Q92993 1/20 0.45
SAE1 Q9UBE0 1/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28284271 0.95 TSHR (0.42) LIPGCYSLTR2CYSLTR1BIDMCL1
SCHEMBL26216122 0.88 KDR (0.43) TP53CYP3A4TSHR
SCHEMBL7336813 0.85 FOLH1 (0.40) CYP3A4
SCHEMBL617126 0.82 LIPG (0.55) LIPGCYSLTR2CYSLTR1BIDMCL1
SCHEMBL10174587 0.82 CLCN2 (0.42) TP53TSHR
SCHEMBL11748079 0.81 LIPG (0.47) LIPGCYSLTR2CYSLTR1BIDMCL1
SCHEMBL298005 0.81 LIPG (0.53) LIPGCYSLTR2CYSLTR1BIDMCL1
SCHEMBL5171335 0.81 FOLH1 (0.59) LIPGCYSLTR2CYSLTR1BIDMCL1
SCHEMBL7652499 0.81 LIPG (0.58) LIPGCYSLTR2CYSLTR1BIDMCL1
SCHEMBL8059017 0.81 LIPG (0.53) LIPGCYSLTR2CYSLTR1BIDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154756-A2 THIONOLACTONES AS ADDITIVES FOR VINYL NETWORK DEGRADATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-08-17 WO disclosed
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US disclosed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US disclosed
EP-2168951-A1 AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF ARSA, AHR, HRH2 LIPG 4573/4885CYSLTR2 19/4885CYSLTR1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.